[{"id":"13801bc2-a2e8-497b-9060-1fd9355fe93c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05320874","created_at":"2022-04-11T13:52:59.045Z","updated_at":"2025-02-25T17:12:10.318Z","phase":"Phase 1","brief_title":"A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.","source_id_and_acronym":"NCT05320874","lead_sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","biomarkers":" HER-2 • KRAS • BRAF • NRAS","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600 • HER-2 expression","tags":["HER-2 • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600 • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • docetaxel • capecitabine • irinotecan • XZP-KM257"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 232","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2022-04-11"}]